Viatris will acquire Pacira BioSciences in a $1.65 billion transaction, agreeing to buy all outstanding Pacira shares for $36.50 each in cash. The deal brings a pain-care portfolio platform into Viatris and consolidates assets in a segment where IP and reimbursement pressures are increasing scrutiny. The transaction is notable for two reasons: it reflects continued consolidation in specialty pharma, and it arrives at a time when portfolios are being reshaped in anticipation of patent expiries and competitive generic entry. For investors and operating teams, the next steps are expected to include integration planning, portfolio reprioritization, and evaluation of pipeline and manufacturing footprints post-close.